Rapha Capital Management

Kevin Slawin, MD, is the Founder and Managing Partner and the only investment professional named on the firm's website. Slawin's background spans robotic surgery, prostate cancer biomarker development, and the founding of Bellicum Pharmaceuticals, which went public in 2014. The firm does not list a separate investment committee, suggesting concentrated decision-making authority.

Rapha Capital co-invests in and operates out of K2 Biolabs, a Houston-based biotech co-working facility co-founded by Kevin Slawin. This physical infrastructure gives Rapha Capital early visibility into startup formation, enabling it to seed companies before traditional venture capital processes engage. Slawin's operating companies — Ponce Therapeutics and DELiver Therapeutics — also generate pipeline through internal R&D programs.

Rapha Capital operates as a private equity firm running 13 managed investment entities and multiple fund vehicles, including Rapha Capital BioVentures Fund I and Rapha Capital PE Life Sciences Fund VI. Functionally, it blends venture investing with a biotech studio model because Slawin personally co-founds and incubates several portfolio companies through K2 Biolabs.

The firm's publicly disclosed vehicles suggest it raises dedicated funds (BioVentures Fund I, PE Life Sciences Fund VI) in addition to holding company-level investment entities. It is not disclosed whether the firm also acts as a limited partner in external venture funds, though its studio model implies the bulk of deployment is direct.

Rapha Capital invests primarily at the seed and early institutional stages. Companies like PrintBio and Phoenix SENOLYTIX entered the portfolio before or during preclinical development, and Slawin's thesis emphasizes identifying disruptive biotechnologies before they surface in broader venture pipelines.

The firm's website and portfolio do not flag explicit exclusions. However, Rapha Capital's entire known portfolio concentrates on life sciences — oncology, immunotherapy, senescence biology, medical devices, and synthetic biology — with no evidence of interest in software, consumer, or non-healthcare deep tech.

The firm's website footer references an 'Arbor Rapha Spac' entity, indicating a historical or active special-purpose acquisition company affiliation. No details on sponsors, target sectors, or transaction history are disclosed on the Rapha Capital site, and the ARBOR name likely signals a joint venture with an external partner.